OmniAb Inc.

OmniAb Inc. operates as a biotechnology company focused on advancing antibody drug discovery technology. Its primary function is to develop and leverage a diverse portfolio of proprietary technologies to facilitate the discovery and development of monoclonal antibodies for therapeutic use. OmniAb Inc.'s offerings impact various sectors, including pharmaceuticals and healthcare, by enabling the creation of novel therapies aimed at treating a multitude of serious diseases. The company's technology platform integrates advanced screening techniques and next-generation sequencing to enhance antibody library creation, screening, and optimization processes. As a significant player in the biotech industry, OmniAb Inc. collaborates with major pharmaceutical companies to accelerate the drug discovery process, providing essential tools and expertise that are integral to developing cutting-edge therapeutics. This positions OmniAb Inc. as a crucial entity in the continuum of biomedical innovation and pharmaceutical advancements.